Anti-human CD73 monoclonal antibody without hook effect
The present invention provides a novel anti-CD73 monoclonal antibody. The antibody has high affinity for human CD73 protein. Both biochemical-level and cell-level experiments show that the antibody is highly effective in inhibiting the enzyme activity of CD73. The in-vivo experiment indicates that the antibody has a significant inhibition effect on tumor cell growth. In particular, the antibody does not have the “hook effect” most prior art antibodies have in connection with inhibition of the enzyme activity of CD73, and is therefore more suitable for clinical use than the prior art antibodies.
1 . An anti-human CD73 monoclonal antibody, comprising: a heavy-chain variable region with complementarity-determining region (CDR) 1, CDR2, and CDR3 that are polypeptides having the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively; and a light-chain variable region with CDR1, CDR2, and CDR3 that are polypeptides having the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO: 6, respectively.
2 . A drug for treating non-small cell lung cancer or melanoma, comprising the monoclonal antibody of claim 1 .
3 . A CD73 enzyme activity inhibitor, comprising the monoclonal antibody of claim 1 .
4 . A method of treating melanoma in a subject, comprising: administering a therapeutically effective amount of the anti-human CD73 monoclonal antibody of claim 1 to the subject.
5 . A method of treating non-small cell lung cancer in a subject, comprising: administering a therapeutically effective amount of the anti-human CD73 monoclonal antibody of claim 4 to the subject.